Trials / Conditions / BCLC Stage C Hepatocellular Carcinoma

BCLC Stage C Hepatocellular Carcinoma

18 registered clinical trials studyying BCLC Stage C Hepatocellular Carcinoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma NCT07274774	Shandong Cancer Hospital and Institute	Phase 2
Recruiting	HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of NCT06632093	First Hospital of China Medical University	—
Recruiting	Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HC NCT06172205	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 3
Recruiting	Liver Cancer and Immunotherapy in the Liquid Biopsy Era NCT05810402	University Hospital, Montpellier	N/A
Terminated	A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezoliz NCT05199285	Academic and Community Cancer Research United	Phase 2
Withdrawn	Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally A NCT05327738	OHSU Knight Cancer Institute	Phase 2
Completed	BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic L NCT05250895	Emory University	EARLY_Phase 1
Terminated	BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer NCT04777708	Jonsson Comprehensive Cancer Center	EARLY_Phase 1
Unknown	TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC NCT04992143	First Affiliated Hospital of Zhejiang University	Phase 2
Completed	Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liv NCT04828486	Mayo Clinic	Phase 2
Active Not Recruiting	Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver NCT04605731	City of Hope Medical Center	Phase 1
Active Not Recruiting	Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresec NCT04736121	Sirtex Medical	N/A
Terminated	Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer NCT04442581	University of Washington	Phase 2
Completed	HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416) NCT06631326	First Hospital of China Medical University	—
Unknown	The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer NCT04204577	Chinese PLA General Hospital	Phase 2
Completed	Pembrolizumab (MK-3475) in Hepatocellular Carcinoma NCT02940496	M.D. Anderson Cancer Center	Phase 2
Completed	Using Machine Learning to Identify Responders to TACE or HAIC for uHCC NCT07368530	First Affiliated Hospital, Sun Yat-Sen University	—
Completed	Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be R NCT01900002	M.D. Anderson Cancer Center	Phase 2